医药销售代表(河南 安阳)YSP
上海中信国健医药发展有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2016-12-30
- 工作地点:安阳
- 招聘人数:1人
- 工作经验:1年经验
- 学历要求:大专
- 职位月薪:4500+ /月
- 职位类别:医药销售代表
职位描述
职位描述:
医药销售代表 (该职位主要负责河南安阳、濮阳地区)
主要职责:
1. 积极实施所辖医院年、季、月度医药销售计划,合理分配和实施销售费用预算;
2. 配合落实市场部的推广活动,以及其他部门(质量、财务和人力资源等)工作;
3. 新客户开拓和上量维护;
4. 协助商务部做好销售订单、履行与管理工作;
5. 按时完成工作报告;
6. 学习产品知识和提高工作技能;
7. 完成上级交付的其他任务。
任职资格:
1.大专及以上学历,医、药学相关专业优先;
2.两年及以上临床医药销售工作经历,有三甲医院风湿科、骨科、皮科销售经验优先;
3.理解公司所经营的产品知识,掌握竞品和行业动态;
4.熟练使用word、excel、ppt等办公软件;
5.良好的人际沟通力、计划执行力、影响能力及客户服务意识和能力。
举报
分享
医药销售代表 (该职位主要负责河南安阳、濮阳地区)
主要职责:
1. 积极实施所辖医院年、季、月度医药销售计划,合理分配和实施销售费用预算;
2. 配合落实市场部的推广活动,以及其他部门(质量、财务和人力资源等)工作;
3. 新客户开拓和上量维护;
4. 协助商务部做好销售订单、履行与管理工作;
5. 按时完成工作报告;
6. 学习产品知识和提高工作技能;
7. 完成上级交付的其他任务。
任职资格:
1.大专及以上学历,医、药学相关专业优先;
2.两年及以上临床医药销售工作经历,有三甲医院风湿科、骨科、皮科销售经验优先;
3.理解公司所经营的产品知识,掌握竞品和行业动态;
4.熟练使用word、excel、ppt等办公软件;
5.良好的人际沟通力、计划执行力、影响能力及客户服务意识和能力。
职能类别: 医药销售代表
关键字: 医药代表 医药销售代表
公司介绍
上海中信国健医药发展有限公司
上海中信国健医药发展有限公司为上海中信国健药业股份有限公司全资子公司。
上海中信国健药业股份有限公司(以下简称“中信国健”)是由中国中信集团有限公司旗下中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来,专注于抗体药物的研发、中试和产业化,现已发展成为国内抗体制药领域的领军企业,提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。
作为一家以研发为基础的生物制药公司,中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术,具备持续开发新药的创新能力。公司生产规模位居行业前列。
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
现由于公司发展需要,诚聘具有创新精神和成就事业理想的优秀人才加盟。
请符合条件的应聘者将中英文简历等信息发送E-mail至:cpgjhr@cpgj-pharm.com (请在邮件题目上注明应聘职位等信息)
上海中信国健医药发展有限公司为上海中信国健药业股份有限公司全资子公司。
上海中信国健药业股份有限公司(以下简称“中信国健”)是由中国中信集团有限公司旗下中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来,专注于抗体药物的研发、中试和产业化,现已发展成为国内抗体制药领域的领军企业,提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。
作为一家以研发为基础的生物制药公司,中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术,具备持续开发新药的创新能力。公司生产规模位居行业前列。
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
现由于公司发展需要,诚聘具有创新精神和成就事业理想的优秀人才加盟。
请符合条件的应聘者将中英文简历等信息发送E-mail至:cpgjhr@cpgj-pharm.com (请在邮件题目上注明应聘职位等信息)
联系方式
- Email:cpgjhr@cpgj-pharm.com
- 公司地址:上班地址:泰安